Lakeshorebio
About Lakeshorebio
Lakeshorebio is a publicly listed company, and was acquired by Oceanpine Capital in November 2025. It operates as a vaccines and immunotherapeutics for infectious diseases are developed. Lakeshorebio has raised $170 million across 5 funding rounds from investors including Orbimed, Haitong International Securities Group and Eight Roads Ventures. The company has 573 employees. Lakeshorebio offers products and services including Rabies Vaccine and Hepatitis Vaccine. Its focus areas include Traditional Pharmaceuticals. Its legal entity is LakeShore Biopharmaceuticals.
Company details
Research, development, and production of vaccines targeting infectious diseases are conducted by Lakeshorebio, a biotechnology firm. PIKA immune modulation technology is utilized in these efforts. The portfolio includes rabies and hepatitis B vaccines, manufactured via various cell lines. Operations focus on immunotherapeutics, with the company maintaining public trading status. The domain lakeshorebio.com is associated with these activities.
- Employees 573
- Stage Acquired
- SectorsHealthcare
- Website lakeshorebio.com
- Acquired by Summit Healthcare Acquisition Corp (Sep 2022)
- Legal Name Lakeshore Biopharma Co., Ltd
- Annual Revenue$85.67 M (USD)6as on Mar 31, 2025
- Net Profit-$13.93 M (USD)77.2as on Mar 31, 2025
- EBITDA-$1.8 M (USD)94.81as on Mar 31, 2025
- Total Equity Funding$170M (USD)
in 5 rounds
- Latest Funding Round$15M (USD), Post-IPO
Jul 2025
- InvestorsOrbimed
& 12 more
- Employee Count573
- Acquired by
Products & Services of Lakeshorebio
Lakeshorebio offers a comprehensive portfolio of products and services, including Rabies Vaccine and Hepatitis Vaccine.
The vaccine is produced using Vero cells for infectious disease prevention
Vaccines for hepatitis are developed using CHO cells and other methods for immune protection
Funding Insights of Lakeshorebio
Lakeshorebio has successfully raised a total of $170M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $170M
- Total Rounds 5
- Last Round Post-IPO — $15M
- Investors Count 12
All 5 funding rounds of Lakeshorebio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $15M | Post-IPO | – | – | – |
| Feb 2024 | $40M | Post-IPO | – | – | – |
| Mar 2022 | $40M | Series B | – | Legend Capital | |
| Feb 2021 | $130M | Series B | – | Oceanpine Capital, Orbimed | |
| Jun 2012 | – | Series A | – | – |
13 investors in total: 13 institutional.
Investors in Lakeshorebio
Lakeshorebio has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Haitong International Securities Group and Eight Roads Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture Capital firm focused on multiple sectors | – | legendcapital.com.cn | Haidian, China | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | – | fprimecapital.com | - | |
Global private equity investments are managed with long-term focus. | – | hillhouseinvestment.com | New York, United States | |
Tech companies are invested in by MSA venture capital fund. | – | msacap.com | Chaoyang, China | |
- | – | 3wpcap.com | - | |
Venture capital is deployed for global health technology innovations. | – | adjuvantcapital.com | New York City, USA | |
Operates as an investment management firm specializing in financial assets. | 2018 | oceanpine.com | Beijing, China | |
Corporate advisory services in international securities are provided. | 1973 | htisec.com | Hong Kong, China |
Investor details for Lakeshorebio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Lakeshorebio
Lakeshorebio is a publicly listed company on the NASDAQ with ticker symbol LSB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date06 Aug 2021
- Listed onNASDAQ: LSB
- Listed entityLakeShore Biopharma Co., Ltd
- Exchange sectorHealth technology
- Share price$0.63 (-20.68% on the day) · 2025-09-22
- Market capitalisation$25.8M
- Volume (last session)942,216
- Analyst consensusNeutral
Financials of Lakeshorebio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $85.7M | -$13.9M | -$1.8M |
| 2023 | $80.8M | -$61.1M | -$34.7M |
Detailed financial statements for Lakeshorebio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Lakeshorebio
5 dated milestones of Lakeshorebio across 13 years, from founding to its latest funding, stage changes and deals.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Summit Healthcare Acquisition Corp.
- Funding Latest funding round, Post-IPO, of $15.0M.
- Exit Acquired by Oceanpine Capital.
Web traffic of Lakeshorebio
The website of Lakeshorebio (lakeshorebio.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▼ 36.6% vs previous month
Top companies in Traditional Health & Nutrition
10 companies that operate in the same segment as Lakeshorebio (Traditional Health & Nutrition), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | – | USD 3.02 B | 8,300 | |
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 89.42 M | 962 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | – | USD 5.1 B | 13,500 | |
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | Petah Tikva, Central District, Israel | USD 500 M | USD 18.74 B | 51,792 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | – | USD 508.93 M | 5,180 | |
Pharmaceutical products are developed and marketed globally. | 2009 | Montville, New Jersey, United States | USD 155.92 M | – | – | |
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | – | USD 6.21 B | 25,870 | |
Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations | 1991 | Delhi, Delhi, India | USD 367.2 M | USD 1.52 B | 21,320 | |
Generics, biosimilars, APIs, and vaccines are manufactured by Wockhardt. | 1967 | Mumbai, Maharashtra, India | – | USD 353.53 M | 3,410 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lakeshorebio
Complete news archive for Lakeshorebio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lakeshorebio
Lakeshorebio is a funded company, having raised a total of $170M across 5 funding rounds to date.
Lakeshorebio has 573 employees.
Annual revenue of Lakeshorebio is $85.67M as on Mar 31, 2025.
Research, development, and production of vaccines targeting infectious diseases are conducted by Lakeshorebio, a biotechnology firm. PIKA immune modulation technology is utilized in these efforts. The portfolio includes rabies and hepatitis B vaccines, manufactured via various cell lines. Operations focus on immunotherapeutics, with the company maintaining public trading status. The domain lakeshorebio.com is associated with these activities.
Lakeshorebio offers Rabies Vaccine and Hepatitis Vaccine.
Yes, Lakeshorebio is publicly traded on NASDAQ under the ticker symbol LSB.
Lakeshorebio has 13 investors. Key investors include Orbimed, Haitong International Securities Group, Eight Roads Ventures, Legend Capital, and XS Xinsheng.
Lakeshorebio operates through Lakeshore Biopharmaceuticals.
Yes. Lakeshorebio was acquired by Summit Healthcare Acquisition Corp in September 2022.